Amer Zeidan, Associate Professor of Medicine (Hematology) at the Yale University, posted on X:
“What a pleasure to present and usher a new era in AML with total oral therapy through ASCERTAIN-V study at ASCO25 All-Oral Regimen of Decitabine-Cedazuridine plus Venetoclax in Newly Diagnosed AML Ineligible for Intensive Induction Chemo.”
More about ASCO 2025 Symposium on OncoDaily.